Recent developments in recombinant protein–based dengue vaccines

NK Tripathi, A Shrivastava - Frontiers in immunology, 2018 - frontiersin.org
Recombinant proteins are gaining enormous importance these days due to their wide
application as biopharmaceutical products and proven safety record. Various recombinant …

Structure and function of capsid protein in flavivirus infection and its applications in the development of vaccines and therapeutics

X Zhang, Y Zhang, R Jia, M Wang, Z Yin, A Cheng - Veterinary research, 2021 - Springer
Flaviviruses are enveloped single positive-stranded RNA viruses. The capsid (C), a
structural protein of flavivirus, is dimeric and alpha-helical, with several special structural …

Dengue viruses and promising envelope protein domain III-based vaccines

H Fahimi, M Mohammadipour… - Applied microbiology …, 2018 - Springer
Dengue viruses are emerging mosquito-borne pathogens belonging to Flaviviridae family
which are transmitted to humans via the bites of infected mosquitoes Aedes aegypti and …

Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus

QH Quach, SK Ang, JHJ Chu, JCY Kah - Acta biomaterialia, 2018 - Elsevier
Dengue results in substantial human morbidity and significant socio-economic impacts, but
a specific dengue therapeutic is not available. The currently available dengue vaccine has …

Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli

SC Araujo, LR Pereira, RPS Alves, R Andreata-Santos… - Vaccines, 2020 - mdpi.com
This article aims to review the present status of anti-flavivirus subunit vaccines, both those at
the experimental stage and those already available for clinical use. Aspects regarding …

The nucleocapsid protein of SARS-CoV-2, combined with ODN-39M, is a potential component for an intranasal bivalent vaccine with broader functionality

Y Lobaina, R Chen, E Suzarte, P Ai, V Huerta… - Viruses, 2024 - mdpi.com
Despite the rapid development of vaccines against COVID-19, they have important
limitations, such as safety issues, the scope of their efficacy, and the induction of mucosal …

[HTML][HTML] Next generation dengue vaccines: a review of the preclinical development pipeline

KS Vannice, JT Roehrig, J Hombach - Vaccine, 2015 - Elsevier
Dengue represents a significant and growing public health problem across the globe, with
approximately half of the world's population at risk. The increasing and expanding burden of …

A tetravalent formulation based on recombinant nucleocapsid-like particles from dengue viruses induces a functional immune response in mice and monkeys

L Gil, K Cobas, L Lazo, E Marcos… - The Journal of …, 2016 - journals.aai.org
Despite the considerable effort that has been invested in elucidating the mechanisms of
protection and immunopathogenesis associated with dengue virus infections, a reliable …

[HTML][HTML] Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates

SP McBurney, JE Sunshine, S Gabriel, JP Huynh… - Vaccine, 2016 - Elsevier
We describe the preclinical development of a dengue virus vaccine targeting the dengue
virus serotype 2 (DENV2) envelope domain III (EDIII). This study provides proof-of-principle …

Dengue vaccination: towards a new dawn of curbing dengue infection

S Jain, N Vimal, N Angmo, M Sengupta… - Immunological …, 2023 - Taylor & Francis
Dengue is an infectious disease caused by dengue virus (DENV) and is a serious global
burden. Antibody-dependent enhancement and the ability of DENV to infect immune cells …